Treatment with CD40 agonist antibody, which promotes differentiation of monocytes and macrophages towards a proinflammatory phenotype, reduced tumor growth and improved survival in <i>B2m</i>-null melanoma and colorectal cancer models. Here, CD40 is linked to melanoma.